Form 4: PharmaCyte Biotech Director Acquires Stock Options

Michael M. Abecassis, a director of PharmaCyte Biotech, Inc., acquired stock options on April 30, 2024.

Summary

• Michael M. Abecassis, a director of PharmaCyte Biotech, Inc., filed a Form 4 regarding changes in beneficial ownership.
• On April 30, 2024, Abecassis acquired 38,009 stock options with an exercise price of $2.12.
• The options vest in full on the date of the Issuer's next annual meeting of stockholders, subject to continued service.
• Following the transaction, Abecassis directly owns 38,009 derivative securities.
• The filing was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: Neutral sentiment as it primarily reports a transaction. The late filing is a minor negative, but the explanation mitigates concern.

Negatives

• The Form 4 filing was submitted late due to an administrative error.

Risks

• The vesting of the stock options is contingent upon Mr. Abecassis' continued service with the company.

Management Comments

• The transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.

Stakeholder Impact

• The acquisition of stock options by a director could potentially align the director's interests with those of the shareholders.

Next Steps

• The options will vest upon the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis.

Key Dates

Keywords

Form 4, stock options, beneficial ownership, director, PMCB, PharmaCyte Biotech, Abecassis